Atrial fibrillation (AF) patients
treated with Xarelto (rivaroxaban)
for stroke prevention have low rates
of bleeding and stroke, reveals realworld
data from the XANTUS study
presented at the European Society
of Cardiology (ESC) Congress.
“With 10 million people in Europe
alone affected by AF, a number
that is only expected to increase,
real-world insights on routine
anticoagulation management
in everyday clinical practice
is increasingly important for
physicians and patients with AF,”
said principal investigator Professor
A. John Camm, professor of clinical
cardiology at St George’s University.
Bayer and Janssen said the results
were generally consistent with
those observed in Phase 3 research
with the XANTUS study and postmarketing
safety surveillance for
Xarelto involving 45,000 patients.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.